+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART)



Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART)



Journal of the Medical Association of Thailand 88(7): 956-966



Background. Previous cross sectional studies revealed that dyslipidemia occurs in 50-70% of children receiving highly active antiretroviral therapy (HAART). However, there is no information in children in developing countries where children may have a different nutritional status.Objective: To evaluate the incidence and associated risk factors of dyslipidemia following HAART in HIV-infected Thai children.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011982476

Download citation: RISBibTeXText

PMID: 16241026


Related references

HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 31(2): 253-255, 2002

Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART). Recenti Progressi in Medicina 95(5): 265-275, 2004

Plasma Mitochondrial Dna Levels as a Biomarker of Lipodystrophy Among Hiv-infected Patients Treated with Highly Active Antiretroviral Therapy (Haart). Current Molecular Medicine 15(10): 975-979, 2015

Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). Current Molecular Medicine 15(10): 975-979, 2016

Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. Journal of the Cardiometabolic Syndrome 3(2): 111-114, 2008

Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. Journal of the Medical Association of Thailand 90(3): 452-458, 2007

Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatric Infectious Disease Journal 32(1): 39-44, 2013

Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 43(1): 121-123, 2006

Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy. Indian Journal of Pediatrics 83(3): 226-231, 2017

Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Medicine 12(1): 54-60, 2011

Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India. African Health Sciences 14(2): 408-413, 2015

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. Journal of the International Aids Society 15(2): 17427, 2012

Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy. Journal of Tropical Pediatrics 57(5): 324-332, 2012

Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. Pharmacoepidemiology and Drug Safety 18(7): 589-594, 2010

Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. Scandinavian Journal of Infectious Diseases 39(9): 799-804, 2007